Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28540379 | 0.76 | GPR3 (0.31) | GPR3 | |
| SCHEMBL720139 | 0.76 | GPR3 (0.54) | GPR3 | |
| SCHEMBL7052017 | 0.70 | GPR3 (0.64) | GPR3 | |
| SCHEMBL28541824 | 0.64 | — | — | |
| SCHEMBL28534627 | 0.64 | — | — | |
| SCHEMBL4408 | 0.63 | KDM4E (0.57) | GPR3 | |
| SCHEMBL129743 | 0.60 | — | — | |
| SCHEMBL7790779 | 0.60 | KDM4E (0.43) | GPR3 | |
| SCHEMBL26597 | 0.59 | KDM4E (0.57) | GPR3 | |
| SCHEMBL588610 | 0.58 | EGFR (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 594 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024140824-A1 | PYRIDAZINE NLRP3 INHIBITOR COMPOUND, PHARMACEUTICAL COMPOSITION, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 长春金赛药业有限责任公司 | 2024-07-04 | — | — | WO | disclosed |
| WO-2024104452-A1 | MC4R ANTAGONIST COMPOUND, PHARMACEUTICAL COMPOSITION AND PHARMACEUTICAL USE THEREOF | 长春金赛药业有限责任公司 | 2024-05-23 | — | — | WO | disclosed |
| WO-2024067675-A1 | FUSED RING KIF18A INHIBITOR COMPOUND, PHARMACEUTICAL COMPOSITION, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 长春金赛药业有限责任公司 | 2024-04-04 | — | — | WO | disclosed |
| WO-2024061357-A1 | HARRINGTONINE DERIVATIVE, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | 南开大学 | 2024-03-28 | — | — | WO | disclosed |
| US-20240009189-A1 | 1,4-DISUBSTITUTED PYRIDAZINE QUINOLNE ANALOGS THERE OF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | NOVARTIS AG (CH) | 2024-01-11 | — | — | US | disclosed |
| US-20230391775-A1 | SUBSTITUTED DIARYLAMINE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | SUZHOU YABAO PHARMACEUTICAL R&D CO., LTD. (CN) | 2023-12-07 | — | — | US | disclosed |
| US-20230390410-A1 | COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY | BIRDIE BIOPHARMACEUTICALS INC (KY) | 2023-12-07 | — | — | US | disclosed |
| US-11833203-B2 | Synthetic retinoids (in cell modulation) | UNIVERSITY OF DURHAM | 2023-12-05 | — | — | US | disclosed |
| EP-4282486-A2 | COMPLEMENT FACTOR B INHIBITOR, AND PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Meiyue Biotech Development Co., Ltd. (CN) | 2023-11-29 | — | — | EP | disclosed |
| US-11786604-B2 | Compounds and compositions for treating HER2 positive tumors | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2023-10-17 | — | — | US | disclosed |
| US-20030225083-A1 | Antidiabetic agents | FAKHOURY STEPHEN A (US) | 2003-12-04 | — | — | US | disclosed |
| US-20030220381-A1 | ANTIDIABETIC AGENTS | WARNER-LAMBERT COMPANY, LLC | 2003-11-27 | — | — | US | disclosed |
| WO-2003084535-A1 | ANTIDIABETIC AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2003-10-16 | — | — | WO | disclosed |
| WO-2003084916-A2 | COMPOUNDS THAT MODULATE PPAR ACTIVITY AND METHODS FOR THEIR PREPARATION | WARNER-LAMBERT COMPANY LLC (US) | 2003-10-16 | — | — | WO | disclosed |
| WO-2003082276-A1 | ANTIDIABETIC AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2003-10-09 | — | — | WO | disclosed |
| US-20030171377-A1 | Antidiabetic agents | BIGGE CHRISTOPHER FRANKLIN (US) | 2003-09-11 | — | — | US | disclosed |
| US-20030162787-A1 | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade | WARNER-LAMBERT COMPANY LLC | 2003-08-28 | — | — | US | disclosed |
| WO-2003045912-A1 | INHIBITORS OF FACTOR XA AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE | WARNER-LAMBERT COMPANY LLC (US) | 2003-06-05 | — | — | WO | disclosed |
| WO-2003018553-A1 | ORAL ANTIDIABETIC AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2003-03-06 | — | — | WO | disclosed |
| EP-1155698-A1 | ORGANOBORON COMPOUNDS EXHIBITING ANTICOCCIDIAL ACTIVITIES | Nitto Kasei Co., Ltd. (JP) | 2001-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171377-A1 | Antidiabetic agents | SLC5A1, SLC5A2, GLP1R | GPR3 3696/4885 |
| US-11833203-B2 | Synthetic retinoids (in cell modulation) | RARA, RARB, RXRA | GPR3 395/4885 |
| US-20030220381-A1 | ANTIDIABETIC AGENTS | GPR119, GCKR, GLP1R | GPR3 2934/4885 |
| US-20240009189-A1 | 1,4-DISUBSTITUTED PYRIDAZINE QUINOLNE ANALOGS THERE OF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | SMN1; SMN2, CLN6, PMP22 | GPR3 3874/4885 |
| US-20030162787-A1 | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade | TFPI, F11, F12 | GPR3 3860/4885 |
| US-20230391775-A1 | SUBSTITUTED DIARYLAMINE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | LRRK2, COMT, PARK7 | GPR3 1297/4885 |
| US-20030225083-A1 | Antidiabetic agents | GPR119, IAPP, SLC5A1 | GPR3 3603/4885 |
| US-11786604-B2 | Compounds and compositions for treating HER2 positive tumors | ERBB2, EGFR, TP53 | GPR3 573/4885 |
| US-20230390410-A1 | COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY | CD47, CD274, TP53 | GPR3 2262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.